-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vedolizumab (VDZ) has been shown to medsci.
Vedolizumab (VDZ) has been shown to medsci.
The researchers used immunohistochemistry to evaluate the staining of colon tissue from human patients with active disease or UC receiving or not receiving vedolizumab.
+
The results of the study showed that vedolizumab significantly reduced the number of CD3 + T cells and CD68 + monocytes/macrophages in the colon of UC patients with active disease .
+ + + +
Figure: Vedolizumab reduces the number of CD3 + T cells and CD68 + monocytes/macrophages in the colon
+ +
This study confirmed that vedolizumab can reduce the number of immune cells in the mucosa of UC patients.
This study confirmed that vedolizumab can reduce the number of immune cells in the mucosa of UC patients.
Original source:
Roberto Manzini.
oup.
com/ibdjournal/advance-article-abstract/doi/10.
1093/ibd/izab063/6224889?redirectedFrom=fulltext" target="_blank" rel="noopener">Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis.
Leave a message here